The other targeting strategy involves the blockade of immune checkpoint inhibitors (e.g., PD-1/PD-L1, CTLA-4, TIM-3, and LAG-3; see Section 5.2) to modulate the immune response towards tumor cells and increase the probability of tumor cell death. This evidence concerns the gene HAVCR2 and neoplasm.